<GlossaryTerm id="CDR0000559139"><TermName>indium In 111-CHX-A DTPA trastuzumab</TermName><TermPronunciation>(IN-dee-um … tras-TOO-zoo-mab)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the imaging of breast cancer and some other types of cancer. It is made by attaching a radioactive substance called indium In 111 to the monoclonal antibody trastuzumab. Trastuzumab binds to the human growth factor receptor 2 (HER2/neu) on some breast cancer cells and on several other types of cancer cells. Indium In 111-CHX-A DTPA trastuzumab is a type of radioimmunoconjugate.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000720441" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;indium In 111 CHX-A DTPA trastuzumab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000720440" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;indio In 111-CHX-A DTPA trastuzumab&quot;" language="es" id="_4"/><SpanishTermName>indio In 111-CHX-A DTPA trastuzumab</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para crear imágenes del cáncer de mama y algunos otros tipos de cáncer. Se elabora mediante la unión de una sustancia radiactiva llamada indio In 111 al anticuerpo monoclonal trastuzumab. El trastuzumab se une al receptor del factor de crecimiento humano 2 (HER2/neu) de algunas células de cáncer de mama y de otros tipos de células cancerosas. El indio In 111 trastuzumab CHX-A DTPA es un tipo de radioimmunoconjugado.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2008-03-31</DateFirstPublished><DateLastModified>2017-10-24</DateLastModified></GlossaryTerm>
